



CHARACTERISATION AND OUTCOMES OF DIFFICULT-TO-TREAT PATIENTS IN AN ITALIAN COHORT OF PLWH STARTING MODERN ART REGIMEN

P065

Gagliardini, Roberta¹; Tavelli, Alessandro²; Rusconi, Stefano³; Lo Caputo, Sergio⁴; Spagnuolo, Vincenzo⁵; Santoro, Maria Mercedes⁶; Costantini, Andrea⁷; Cicalini, Stefania¹; Maggiolo, Franco⁸; Giacomelli, Andrea⁹; Burastero, Giulia¹⁰; Agrati, Chiara¹¹; Madeddu, Giordano¹²; Quiros Roldan, Eugenia¹³; d'Arminio Monforte, Antonella¹⁴; Antinori, Andrea¹; Cozzi-Lepri, Alessandro¹⁵

1. INMI L Spallanzani IRCCS, UOC Immunodeficienze Virali, Roma, Italy; 2. Icona Foundation, Icona, Milan, Italy; 3. Ospedale Civile di Legnano, Infectious Diseases Unit, Legnano, Italy; 4. University of Foggia, Infectious Diseases Unit, Foggia, Italy; 5. IRCCS San Raffaele Scientific Institute, Infectious Diseases Unit, Milan, Italy; 6. University of Rome Tor Vergata, Department of Experimental Medicine, Rome, Italy; 7. AOJ Ospedali Riuniti, Marche Polytechnic University, Clinical Immunology Unit, Ancona, Italy; 8. ASST Papa Giovanni XXIII, Infectious Diseases Unit, Bergamo, Italy; 9. ASST Fatebenefratelli Sacco, Ospedale Luigi Sacco, III Infectious Diseases Unit, Milano, Italy; 10. Azienda Ospedaliero-Universitaria di Modena, Infectious Disease Clinic, Modena, Italy; 11. INMI L. Spallanzani IRCCS, Cellular Immunology and Pharmacology Unit, Roma, Italy; 12. University of Sassari, Department of Medical, Surgical, and Experimental Sciences, Sassari, Italy; 13. University of Brescia and ASST Spedali Civili di Brescia, Department of Infectious and Tropical Diseases, Brescia, Italy; 14. University of Milan, Department of Health Sciences, Milano, Italy; 15. Institute for Global Health, UCL, Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), London, UK.



BACKGROUND

- ✓ In the last years, almost 30% of PLWH discontinue 1st-line ART (≥1 drug) and 12-20% of PLWH interrupt 2nd-line ART (≥ 1 drug) within 1 year;
- ✓ Treatment failures to modern ART regimens are of concern, as they might limit future drug options and lead to clinical failure
- ✓ Real world estimates of rate of multiple failures to modern regimens are lacking and long-term consequences remain unclear.

AIM

Primary objective

To estimate and characterize the proportion of subjects defined as “difficult to treat” in recent years

STUDY DESIGN AND METHODS

Study population: adult HIV+ pts enrolled in Icona Foundation Study starting a **modern ART**, defined as:

- 2NRTI (TAF, TDF, ABC, 3TC or FTC) + DRV/b qd or + any INSTI or + DOR or + RPV
- DTG+3TC

Classified as “difficult to treat” (DTT) if, after starting ART, experienced ≥1 of the following events:

- ≥2 VF (VF defined as 2 consecutive viral load, VL>50 copies/mL) with or without subsequent ART change;
- ≥2 treatment discontinuations due to toxicity/intolerance/failure on 2 different regimens;
- ≥1 VF followed by ART change plus ≥1 treatment discontinuation due to toxicity/intolerance/failure.

Time to fulfill DTT definition at its first occurrence (index date) was estimated using the Kaplan-Meier method.

We then identified PLWH who, after the same time from starting ART, were still free from DTT events. In a subset of these who subsequently initiated a new regimen, we compared the treatment response between DTT (**exposed**) and **matched unexposed** with respect to the following **endpoints**:

- VF
- discontinuation of ≥1 drug due to intolerance/toxicity/failure;
- treatment failure (composite of VL>200 cp/ml or discontinuation of ≥1 drug due to intolerance/toxicity/failure);
- clinical failure: AIDS/death, SNAE (serious non-AIDS event)/death.

Statistical analysis:

- Chi-square test for categorical and non-parametric Mann-Whitney test for continuous variables;
- Weighted and standard unweighted survival analysis by KM curves and Cox regression model were employed, adjusted for age, VL at ART starting, calendar year of ART and nationality.

RESULTS

Among 8,061 PLWH included, **320 (4%)** experienced one of the DTT-defining events (75% had 2 discontinuations, 18% had 1 VF + 1 discontinuation, 7% had 2 VF).

Table 1 – Patients' characteristics


	Difficult to treat (n=320)	Not difficult to treat (n=7741)	P-value	Overall population (n=8061)
Female gender, n (%)	61 (19.1%)	1412 (18.2%)	0.709	1473 (18.3%)
Age, median (IQR)	43 (36, 50)	39 (31, 49)	<.001	40 (31, 49)
Mode of HIV transmission, n(%)				
IVDU	22 (6.9%)	464 (6.1%)	0.075	486 (6.1%)
MSM	137 (43.2%)	3774 (49.4%)		3911 (49.2%)
heterosexual	141 (44.1%)	2895 (37.4%)		3036 (37.7%)
Other/unknown	17 (5.4%)	503 (6.6%)		520 (6.5%)
CDC stage C, n(%)	55 (17.2%)	763 (9.9%)	<.001	818 (10.1%)
HCV Ab, n(%)				
negative	230 (71.9%)	5774 (74.6%)	0.002	6004 (74.5%)
positive	33 (10.3%)	438 (5.7%)		471 (5.8%)
missing	57 (17.8%)	1529 (19.8%)		1586 (19.7%)
HBsAg, n(%)				
negative	254 (79.4%)	6177 (79.8%)	0.824	6431 (79.8%)
positive	1 (0.3%)	13 (0.2%)		14 (0.2%)
missing	65 (20.3%)	1551 (20.0%)		1616 (20.0%)
Nadir CD4+, cell/mm³, median (IQR)	285 (104, 453)	348 (164, 510)	<.001	346 (160, 508)
CD4+ at BL, cell/mm³, median (IQR)	305 (105, 473)	355 (167, 534)	<.001	353 (163, 532)
Viral load, log₁₀ copies/mL, median (IQR)	4.93 (4.34, 5.42)	4.72 (4.11, 5.30)	0.001	4.73 (4.12, 5.31)
Time from HIV diagnosis to date of starting ART, months, median (IQR)	1 (1, 12)	1 (1, 6)	0.186	1 (1, 6)
Calendar year of BL, median (IQR)	2014 (2013, 2016)	2016 (2015, 2018)	<.001	2016 (2015, 2018)
Not Italian nationality, n (%)	97 (30.3%)	4171 (53.9%)	<.001	4268 (52.9%)
Anchor drug started				
NNRTI	37 (12%)	1469 (19%)	<.001	1506 (19%)
PI	149 (47%)	1568 (20%)		1717 (21%)
INSTI	134 (42%)	4704 (61%)		4838 (60%)

Estimates of becoming difficult-to-treat

- ✓ Estimated probability of becoming DTT: 6.5% (95% CI 5.8- 7.4%) by 6 years.
- ✓ PLWH with advanced HIV disease (CD4<200 and/or AIDS) were 2,402 (30%): more frequently females, infected through heterosexual contacts, not Italians, older and had greater viral load than PLWH without advanced HIV disease.
- ✓ PLWH with advanced HIV disease had higher aHR of becoming DTT (aHR=1.30, 95% CI 0.98-1.74, p=0.072) when compared to PLWH without advanced HIV.

Outcomes of difficult-to-treat patients

Matched analysis performed in 286 DTT and 572 matched-unexposed.



CONCLUSIONS

A total of 6.5% of PLWH who started a modern first-line ART satisfied our arbitrary definition of DTT by 6 years from ART initiation. This appears to be a more vulnerable PLWH population who may experience a higher risk of treatment and clinical failure in the long-term.

Acknowledgments- Icona Foundation Study Group

BOARD OF DIRECTORS: A d'Arminio Monforte (President), A Antinori (Vice-President), S Antinori, A Castagna, F Castelli, R Cauda, G Di Perri, E Girardi, R Iardino, A Lazzarin, GC Marchetti, C Mussini, L Sarmati, F von Schloesser, P Viale. **SCIENTIFIC SECRETARY:** A d'Arminio Monforte, A Antinori, A Castagna, F Ceccherini-Silberstein, A Cingolani, A Cozzi-Lepri, E Girardi, A Gori, S Lo Caputo, G Marchetti, F Maggiolo, C Mussini, M Puoti, CF Perno. **STEERING COMMITTEE:** C Agrati, A Antinori, F Bai, A Bandera, S Bonora, A Calcagno, D Canetti, A Castagna, F Ceccherini-Silberstein, A Cervo, S Cicalini, A Cingolani, P Cinque, A Cozzi-Lepri, A d'Arminio Monforte, A Di Biagio, R Gagliardini, A Giacomelli, E Girardi, N Gianotti, A Gori, G Guaraldi, S Lanini, G Lapadula, M Lichtner, A Lai, S Lo Caputo, G Madeddu, F Maggiolo, V Malagnino, G Marchetti, C Mussini, S Nozza, CF Perno, S Piconi, C Pinnetti, M Puoti, E Quiros Roldan, R Rossotti, S Rusconi, MM Santoro, A Saracino, L Sarmati, V Spagnuolo, N Squillace, V Svircher, L Taramasso, A Vergori. **STATISTICAL AND MONITORING TEAM:** F Bovis, A Cozzi-Lepri, I Fantì, M Ponzano, A Rodano, A Tavelli, F Vinci. **COMMUNITY ADVISORY BOARD:** A Bove, M Cernuschi, L Cosmaro, M Errico, A Perziano, V Calvino. **BIOLOGICAL BANK INMI AND SAN PAOLO:** S Carrara, S Graziano, G Prota, S Truffa, D Vincenti, Y D'Errico. **PARTICIPATING PHYSICIANS AND CENTERS:** A Giacomelli, A Costantini, V Barocci (Ancona); A Saracino, C Santoro, E Milano (Bari); F Maggiolo, C Suardi (Bergamo); P Viale, V Donati, G Verucchi (Bologna); E Quiros Roldan, C Minardi, (Brescia); B Menzaghi, C Abeli (Busto Arsizio); L Chessa, F Pes (Cagliari); P Maggi, L Alessio (Caserta); B Capopardo, B Celestia (Catania); J Vecchiet, K Falasca (Chieti); A Pan, S Dal Zoppo (Cremona); L Sighinolfi, D Segala (Ferrara); F Vichi, MA Di Pietro (Firenze); T Santantonio, S Ferrara (Foggia); M Bassetti, E Pontali, A Alessandrini, N Bobbio, G Mazarro (Genova); M Lichtner, L Fondaco (Latina); S Piconi, C Molteni (Lecco); A Chiodera, P Milini (Macerata); G Nunnari, G Pellicano (Messina); A d'Arminio Monforte, S Antinori, A Lazzarin, G Rizzardi, M Puoti, A Gori, A Castagna, A Bandera, V Bono, MV Cossu, A Giacomelli, R Lolatto, MC Moloi, L Pezzati, C Tincati (Milano); C Mussini, C Puziolante (Modena); P Bonfanti, G Lapadula (Monza); V Sangiovanni, I Gentile, V Esposito, G Di Flumeri, G Di Filippo, V Rizzo (Napoli); AM Cattelan, S Marinello (Padova); A Cascio, C Colomba (Palermo); D Francisci, E Schiaroli (Perugia); G Parruti, F Sozio (Pescara); P Blanc, A Vivarelli (Pistoia); C Lazzaretti, R Corsini (Reggio Emilia); M Andreoni, A Antinori, R Cauda, C Mastroianni, A Cingolani, V Mazzotta, S Lamonica, M Capozzi, A Mondì, M Rivano Capparuccia, G Ialoni, C Stingone, L Gianserra, J Paulicelli, MM Plazzi, G d'Ettore, M Fusto (Roma); M Cecchetto, F Viviani (Rovigo); G Madeddu, A De Vito (Sassari); M Fabbiani, F Montagnani (Siena); A Franco, R Fontana Del Vecchio (Siracusa); BM Pasticci, C Di Giuli (Terni); GC Orofino, G Calleri, G Di Perri, S Bonora, G Accardo (Torino); C Tascini, A Londero (Udine); V Mantrin, G Battagin (Vicenza); G Starini, A Ialungo (Viterbo).

Funding

ICONA Foundation is supported by unrestricted grants from, Gilead Sciences, Janssen-Cilag, MSD, Thera Technologies and Viiv Healthcare

Contact Information

Roberta Gagliardini
roberta.gagliardini@inmi.it